The announcement of a feasibility study by KORU Medical Systems to explore new market opportunities in ambulatory infusion settings with a commercialized biologic suggests a strategic move to expand its product offerings and market presence. This could potentially lead to increased investor interest and positive market sentiment towards KRMD, reflecting in a likely uptick in its stock price in the short term.